EGFR and lung carcinoma: The observation that oncologists practicing in Boston are most likely to order lung cancer molecular tests was consistent with the fact that EGFR mutations conferring responsiveness to EGFR inhibitors were discovered in the Boston-based Harvard Comprehensive Cancer Centers [29, 39, 40].